1 min read
Add as a preferred source on Google

Munich Court Overturns Injunction Against Merck in Keytruda Patent Dispute

The dispute involves Halozyme and Merck over Merck’s injectable version of Keytruda.

Wet courthouse steps lead toward a stone entrance beneath a gray sky / TokenPost.ai
Wet courthouse steps lead toward a stone entrance beneath a gray sky / TokenPost.ai

Halozyme shares fell Thursday after a Munich court overturned a preliminary injunction against Merck in a patent dispute over Merck’s injectable version of Keytruda.

The injunction was issued last year. The patent dispute involves Halozyme and Merck over Merck’s injectable version of Keytruda.

Riza Dagoc

Riza Dagoc reports on regulation, investing and the digital-asset business for TokenPost. Send corrections or tips to info@tokenpost.com.

Loading…